Insights & news

Medicines Cooperation - Sweden to Join International Horizon Scanning Initiative

  • 05/09/2019
  • News

On 4 September 2019, the Dutch Minister for Medical Care, Bruno Bruins, announced plans for Sweden to join the impending International Horizon Scanning Initiative (“IHSI”) (see, attached press release). IHSI, which is expected to start in October 2019, is a form of international cooperation that seeks to identify innovative medicines before they reach the market. It will inform decision-making on treatment and budgets in the participating countries. IHSI is just one example of a broader trend of expanding international cooperation on medicines in a range of areas and in varying geographical constellations.
 
Last month, Minister Bruins had already announced that Canada would also become a member of IHSI (see, Van Bael & Bellis Life Sciences Newsflash of 18 July 2019). When airing the intentions of Sweden, Minister Bruins expressed the hope that IHSI would be able to begin operations with 10 member countries. Other known aspiring members include Belgium, Ireland, Luxemburg and The Netherlands.     

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 31/03/2020
    • Articles

    Pharmaceuticals Remain Focus for Belgian Competition Authority in 2020

    The Belgian Competition Authority (“BCA”) has just published its annual policy note which sets out its enforcement priorities for the year (see, attachments). The pharmaceutical sector is once more one of the BCA’s principal targets for action and, as the BCA indicates, this is not different from an approach followed by other competition authorities around Europe. The BCA is known to be pursuing cases in the sector actively (see e.g., Van Bael & Bellis Life Sciences News alert of 8 October 2019). It also adopted several infringement decisions against a pharmacists’ association in 2019 (see e.g., Van Bael & Bellis Life Sciences News alerts of 5 June 2019, 24 June 2019 and 17 October 2019). Additionally, its chief prosecutor in competition matters had occasion to explain the BCA’s handling of the sector during a hearing of the federal Chamber of Representatives in October 2019 (https://www.dekamer.be/FLWB/PDF/55/0758/55K0758001.pdf). Apart from the pharmaceutical sector and in line with previous years, the BCA will target distribution, logistics, service providers and telecommunications and will continue to monitor procurement matters. Finally, it will also tackle the digital economy.

    Read more
    • 30/03/2020
    • Articles

    European Commission Offers Guidance on Foreign Direct Investment and Protection of Europe’s Healthcare Capacities

    On 25 March 2020, the European Commission (the Commission) published guidance to the Member States of the EU concerning the limitation of foreign direct investment (“FDI”) and free movement of capital from third countries in order to protect Europe’s strategic assets, especially its healthcare capacities (see, attachment). The Commission considers that, in the context of the COVID-19 pandemic, there could be “an increased risk of attempts from non-EU investors to acquire healthcare capacities (for example for the production of medical or protective equipment) or related industries such as research establishments (for instance developing vaccines) via foreign direct investment”. According to the Commission, if left unchecked, FDI could hamper the EU’s capacity to cover the health needs of its citizens. Since the responsibility for screening FDI lies with EU Member States, the Commission calls upon them to (i) make full use of their screening mechanisms “to take fully into account the risks to critical health infrastructures, supply of critical inputs, and other critical sectors”; and (ii) to set up a screening mechanism if they do not yet have one “and in the meantime to use all other available options”. EU Member States should thus avert FDI liable to “create a risk to security or public order in the EU, including a risk to critical health infrastructures and supply of critical inputs”. The Commission also refers to Regulation (EU) 2019/452 establishing a framework for the screening of FDI into the Union (FDI Screening Regulation), which will apply as of 11 October 2020. The FDI Screening Regulation lists critical health infrastructure among the factors which may be taken into consideration in determining whether FDI is likely to affect security or public order. The FDI Screening Regulation also sets up a cooperation mechanism between the Commission and Member States in order to tackle FDI that creates risks in several Member States. Finally, the Commission provides guidance on the possible justifications for restricting capital movements.

    Read more
    • 30/03/2020
    • Articles

    OECD and EUIPO Publish Joint Report on Trade in Counterfeit Pharmaceutical Products - Interpol Also Active

    The Organisation for Economic Co-operation and Development (OECD) and the European Union Intellectual Property Office (EUIPO) published on 23 March 2020 a joint report on trade in counterfeit pharmaceutical products (see, first attachment – the Illicit Trade Report). The Illicit Trade Report covers for the period 2014-2016 illicit traded pharmaceuticals that infringe trade mark rights. In 2016 alone, that trade was worth USD 4.4 billion. By contrast, the Illicit Trade Report does not address the large volume of domestically produced and consumed illicit pharmaceuticals which is a further illustration of the scale of the problem.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *